Northwest Biotherapeutics, Inc. (NWBO)
| Market Cap | 1.17B |
| Revenue (ttm) | 1.69M |
| Net Income (ttm) | -242.65M |
| Shares Out | 747.75M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 25 |
| Last Price | $1.47 |
| Previous Close | $1.50 |
| Change ($) | -0.03 |
| Change (%) | -1.70% |
| Day's Open | 1.52 |
| Day's Range | 1.43 - 1.58 |
| Day's Volume | 1,808,022 |
| 52-Week Range | 0.141 - 2.51 |
News
NWBO has run an 18-year long trial in GBM, one of the deadliest of cancers. It has been mired in controversies, and it has no cash.
In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.
About NWBO
Northwest Biotherapeutics, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L that is in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, which is in Phase I/II clinical trials to treat various inoperable solid tumor cancers. The company was foun... [Read more...]
| Industry Biotechnology | Founded 1996 |
| CEO Linda Powers | Employees 17 |
| Stock Exchange OTCMKTS | Ticker Symbol NWBO |
Financial Performance
In 2019, NWBO's revenue was $2.41 million, an increase of 484.95% compared to the previous year's $412,000. Losses were -$20.30 million, -43.30% less than in 2018.